RedHill Biopharma Receives Notice of Allowance of Fifth U.S. Patent Covering RHB-104 Phase III Crohn’s Disease Program
Once granted, the new U.S. patent covering methods of use for RHB-104 is expected to be valid through 2029 RHB-104 is undergoing a first Phase III study for the treatment of Crohn’s disease in the U.S. and additional countries, with interim analysis …